Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

T Cell Depletion

Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback

Bone Marrow Transplantation volume 32, pages 23–30 (2003)Cite this article

Summary:

We evaluated the outcome of 29 patients (age 22–60 years), who received a CD34+selected related (n=16) or unrelated graft (n=13) with limited T-cell addback (TCAB) (median 5.9 × 104/kg) following full-intensity conditioning for haematological malignancies. In all, 16 patients (55%) had either advanced disease or previous transplants. The cumulative incidences of grade 2–4 acute GVHD were 15.4 and 19.2% and that for chronic extensive GVHD were 35 and 37% in related and unrelated graft recipients, respectively. The strongest predictor of nonrelapse mortality and overall survival was the absolute lymphocyte count (ALC) at 30 days; patients with ALC<0.35 × 109/l having an NRM and OS of 59.2 and 24.7%, compared to 10 and 90% in those with a higher ALC. Patients with acute leukaemia had poorer survival and this was associated with a lower ALC as well. Thus, TCAB with a CD34+ selected graft resulted in a comparable outcome in both older and younger patients, but the survival was strongly influenced by early lymphocyte recovery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

    Article  Google Scholar 

  2. Popplewell LL, Forman SJ . Is there an upper age limit for bone marrow transplantation. Bone Marrow Transplant 2002; 29: 277–284.

    Article  CAS  Google Scholar 

  3. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  Google Scholar 

  4. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  CAS  Google Scholar 

  5. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761–767.

    Article  CAS  Google Scholar 

  6. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  Google Scholar 

  7. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  Google Scholar 

  8. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  Google Scholar 

  9. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.

    CAS  Google Scholar 

  10. Marks DI, Bird JM, Vettenranta K et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646–653.

    Article  CAS  Google Scholar 

  11. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581–4590.

    CAS  Google Scholar 

  12. Chakrabarti S, MacDonald D, Hale G et al. T cell depletion with campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109–118.

    Article  Google Scholar 

  13. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 9: 467–480.

    Google Scholar 

  14. Davison GM, Novitzky N, Kline A et al. Immune reconsti-tution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341–1347.

    Article  CAS  Google Scholar 

  15. Martinez C, Urbano-Ispizua A, Rozman C et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999; 27: 561–568.

    Article  CAS  Google Scholar 

  16. Watts MJ, Somervaille TC, Ings SJ et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol 2002; 118: 117–123.

    Article  Google Scholar 

  17. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  CAS  Google Scholar 

  18. Chakraverty R, Robinson S, Peggs K et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 827–834.

    Article  CAS  Google Scholar 

  19. Sutherland R, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34 enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. J Hematother 1996; 3: 213–226.

    Article  Google Scholar 

  20. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  22. Schattenberg A, Schaap N, Preijers F et al. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant 2000; 26: 17–22.

    Article  CAS  Google Scholar 

  23. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770–773.

    CAS  Google Scholar 

  24. Bornhauser M, Platzbecker U, Theuser C et al. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002; 118: 1095–1103.

    Article  Google Scholar 

  25. Pavletic ZS, Joshi SS, Pirruccello SJ et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33–41.

    Article  CAS  Google Scholar 

  26. Einsele H, Ehninger G, Steidle M et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalo- virus infection after bone marrow transplantation. Blood 1993; 82: 1672–1678.

    CAS  Google Scholar 

  27. Chakrabarti S, Mautner V, Osman H et al. Adenovirus infections following allogeneic stem cell transplantation: the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery. Blood 2002; 100: 1619–1627.

    Article  CAS  Google Scholar 

  28. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72: 1460–1463.

    Article  CAS  Google Scholar 

  29. Storek J, Gooley T, Witherspoon RP et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54, 131–138.

    Article  CAS  Google Scholar 

  30. Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481–3486.

    CAS  Google Scholar 

  31. Kumar S, Chen MG, Gastineau DA et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951–956.

    Article  CAS  Google Scholar 

  32. Bunjes D, Hertenstein B, Wiesneth M et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant 1995; 15: 563–568.

    CAS  Google Scholar 

  33. Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243–2245.

    Article  CAS  Google Scholar 

  34. Brunet S, Urbano-Ispizua A, Ojeda E et al. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114: 544–550.

    Article  CAS  Google Scholar 

  35. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    Article  CAS  Google Scholar 

  36. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  Google Scholar 

  37. Korbling M, Anderlini P . Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900–2908.

    Article  CAS  Google Scholar 

  38. Urbano-Ispizua A, Rozman C, Pimentel P et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100: 724–727.

    Article  CAS  Google Scholar 

  39. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383–387.

    Article  CAS  Google Scholar 

  40. Rebello P, Cwynarsky K, Varughese M et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy 2002; 3: 261–267.

    Article  Google Scholar 

  41. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of CMV infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363.

    Article  CAS  Google Scholar 

  42. Chakrabarti S, Fegan C, Milligan DW . Campath-1H in the bag for T cell depletion in allogeneic peripheral blood stem cell transplantation from related and unrelated donors reduces both acute and chronic GVHD and limits transplant-related mortality. Bone Marrow Transplant 2002; 28 (Suppl. 2): 446.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult Bone Marrow Transplant Unit, Bristol Royal Hospital for Sick Children, Bristol, UK

    S Chakrabarti, J Brown, D H Pamphilon & D I Marks

  2. Stem Cell Laboratory, National Blood Services, Bristol, UK

    M Guttridge, D H Pamphilon & A Lankester

Authors
  1. S Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Guttridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D H Pamphilon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Lankester
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D I Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chakrabarti, S., Brown, J., Guttridge, M. et al. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant 32, 23–30 (2003). https://doi.org/10.1038/sj.bmt.1704082

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704082

Keywords

This article is cited by

Search

Advanced search

Quick links